(Q37098995)

18 August 2017

1 reference

title

Epidemiology and management of cryptococcal meningitis: developments and challenges (English)

1 reference

18 August 2017

1 reference

1 reference

cryptococcal meningitis

1 reference

based on heuristic

inferred from title

author

Eleftherios Mylonakis

series ordinal

2

object named as

Eleftherios Mylonakis

1 reference

18 August 2017

Read Pukkila-Worley

1

1 reference

PubMed ID

18312157

18 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

Expert Opinion on Pharmacotherapy

18 August 2017

1 reference

18 August 2017

9

1 reference

18 August 2017

4

1 reference

18 August 2017

551-560

1 reference

(1557) Proposal to Conserve the Name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae)

18 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Cryptococcosis in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Early mycological treatment failure in AIDS-associated cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Activity of posaconazole in the treatment of central nervous system fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Acetazolamide therapy and intracranial pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Ventriculoperitoneal shunt in cryptococcal meningitis with hydrocephalus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Shunt surgery for hydrocephalus complicating cryptococcal meningitis in human immunodeficiency virus-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Successful use of amphotericin B lipid complex in the treatment of cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

Fungal Burden, Early Fungicidal Activity, and Outcome in Cryptococcal Meningitis in Antiretroviral-Naive or Antiretroviral-Experienced Patients Treated with Amphotericin B or Fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.4.551

21 January 2018

Identifiers

DOI

10.1517/14656566.9.4.551

1 reference

18 August 2017

1 reference

PubMed ID

18312157